Aleksandar Videnovic, MD
Neurology · Boston, MANPI 1093760027
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,364 of the $38,904 with a category attached, or 78.0%. 7 manufacturers reported payments, led by AstraZeneca at 51.6% of the total. Reporting peaked in 2019 at $18,425 and has fallen 83.7% since, to $3,000 in 2023.
Across 27 payments — averaging $1440.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$20K
- F. Hoffmann-la Roche AG$12K
- Travere Therapeutics, Inc.$3K
- Jazz Pharmaceuticals Inc.$3K
- Biogen$1K
- Vertex$367
- plus $50 from 1 others
Across 36 payments — averaging $19,676 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$545K
- Travere Therapeutics, Inc.$147K
- Jazz Pharmaceuticals Inc.$10K
- AstraZeneca$7K
What the payments were for
- Consulting fees$30,36478%
- Travel & lodging$8,29821%
- Food & beverage$2421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $20,063 |
| F. Hoffmann-la Roche AG | 4 | $11,561 |
| Travere Therapeutics, Inc. | 3 | $3,057 |
| Jazz Pharmaceuticals Inc. | 2 | $2,500 |
| Biogen | 1 | $1,307 |
| Vertex | 1 | $367 |
| Neurocrine Biosciences, Inc. | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$11,561
- SUNOSI$2,500
How this compares
$38,904 in reported general payments places this provider in the 85th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 13 | $33,286 |
| NeuproRotigotine | 12 | $21,565 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 250 | $8,847 |
| Entacapone | 39 | $4,844 |
| AmantadineAmantadine Hcl | 42 | $3,155 |
| Rivastigmine | 11 | $2,744 |
| Midodrine Hcl | 19 | $2,333 |
| RivastigmineRivastigmine Tartrate | 30 | $2,182 |
| Pyridostigmine Bromide | 20 | $1,531 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 36 | $1,208 |
| Rasagiline Mesylate | 11 | $1,053 |
| Clonazepam | 83 | $945 |
| Escitalopram Oxalate | 50 | $708 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 37 | $627 |
| Gabapentin | 50 | $469 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boston
- Christopher WrightBoston$2.5M
- Thomas ScammellBoston$617K
- Alfred SandrockBoston$490K
- Pushpa NarayanaswamiBoston$420K
- Roy FreemanBoston$390K
- Michael LevyBoston$387K
- Leeann BurtonBoston$325K
- Ilena GeorgeBoston$316K
- Andrew BudsonBoston$304K
- Denis BalabanBoston$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.